Effect of Selective Serotonin Reuptake Inhibitors via 5-HT1A Receptors on L-DOPA-Induced Rotational Behavior in a Hemiparkinsonian Rat Model

• Main Authors: Masatoshi Inden, Mari Abe, Hideaki Minamino, Kazuyuki Takata, Kanji Yoshimoto, Ikuo Tooyama, Yoshihisa Kitamura
• Format: Article
• Language: English
• Published: Elsevier 2012-01-01
• Series: Journal of Pharmacological Sciences
• Online Access: http://www.sciencedirect.com/science/article/pii/S1347861319305195

l-Dihydroxyphenylalanine (l-DOPA) is considered the gold standard for the treatment of Parkinson’s disease (PD). However, long-term administration of l-DOPA can induce abnormal side effects. On the other hand, selective serotonin reuptake inhibitors (SSRIs) including fluoxetine have gained tremendous popularity in the treatment of depression in PD. SSRIs are thought to influence motor function in PD via pharmacological modification of interactions between serotonergic and dopaminergic networks, which are complex and not yet fully understand. In this study, intranigral injection of 6-hydroxydopamine (6-OHDA) in rats caused a significant loss of tyrosine hydroxylase immunoreactivity in the striatum and substantia nigra. However, tryptophan hydroxylase immunoreactivity of the striatum and raphe nucleus was unaffected by 6-OHDA. Immunohistochemical analysis reveal that the serotonergic system was unaffected by the injection of 6-OHDA. We demonstrated also that pre-treatment with fluoxetine significantly suppressed l-DOPA-induced rotational behavior. Additionally, fluoxetine suppressed l-DOPA-induced ERK1/2 and histone H3 phosphorylation. These effects of fluoxetine were abolished by pre-treatment with WAY 100135, a 5-HT1A antagonist. These results suggest that fluoxetine may influence motor function in PD via pharmacological modification of interactions between serotonergic and dopaminergic neuronal networks. Keywords:: Parkinson’s disease, selective serotonin reuptake inhibitor, fluoxetine, l-dihydroxyphenylalanine, 6-hydroxydopamine